{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:54:39Z","timestamp":1782604479152,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","rheumatic.theclinics.com","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:22:32Z","timestamp":1709889752000},"page":"313-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Imaging in Rheumatic Immune-related Adverse Events"],"prefix":"10.1016","volume":"50","author":[{"given":"Jeremy","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoning","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibiyemi","family":"Oke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ladouceur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rdc.2024.02.005_bib1","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.rdc.2024.02.005_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune Checkpoint Inhibitor\u2013Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.005_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy","volume":"33","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"36","key":"10.1016\/j.rdc.2024.02.005_bib7","first-page":"4073","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib9","doi-asserted-by":"crossref","first-page":"e200032","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor\u2013Induced Inflammatory Arthritis","volume":"3","author":"Subedi","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.005_bib10","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce \u2014 Part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D\u2019Agostino","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.005_bib11","doi-asserted-by":"crossref","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.005_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR Open Rheumatology"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.005_bib13","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib14","doi-asserted-by":"crossref","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.005_bib15","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1007\/s00330-017-4931-8","article-title":"Dual energy CT iodine map for delineating inflammation of inflammatory arthritis","volume":"27","author":"Fukuda","year":"2017","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.005_bib16","doi-asserted-by":"crossref","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.rdc.2024.02.005_bib17","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1136\/annrheumdis-2020-217381","article-title":"Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"van der Geest","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4081\/reumatismo.2020.1297","article-title":"Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab","volume":"72","author":"Perrotta","year":"2020","journal-title":"Reumatismo"},{"issue":"7","key":"10.1016\/j.rdc.2024.02.005_bib19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-017-2410-x","article-title":"Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment","volume":"143","author":"Nakamagoe","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib20","first-page":"129","article-title":"Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non-Small Cell Lung Cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J\u00a0Immunother"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12328-023-01800-2","article-title":"Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma","volume":"16","author":"Dosoden","year":"2023","journal-title":"Clin J Gastroenterol"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2967\/jnmt.121.262151","article-title":"Immune Checkpoint Inhibitor-Related Adverse Effects and 18F-FDG PET\/CT Findings","volume":"49","author":"Schierz","year":"2021","journal-title":"J\u00a0Nucl Med Technol"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib23","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Martin de Fremont","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.005_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1684\/ejd.2016.2837","article-title":"Polymyalgia rheumatica occurring during treatment with ipilimumab","volume":"26","author":"Maniu","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.005_bib25","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/rheumatology\/kew202","article-title":"Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study","volume":"55","author":"Sondag","year":"2016","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.rdc.2024.02.005_bib26","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/rheumatology\/kex376","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients","volume":"57","author":"Henckaerts","year":"2018","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.005_bib27","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rdc.2024.02.005_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib33","doi-asserted-by":"crossref","first-page":"e12954","DOI":"10.1111\/bpa.12954","article-title":"MRI and muscle imaging for idiopathic inflammatory myopathies","volume":"31","author":"Malartre","year":"2021","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib34","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/BOR.0000000000000326","article-title":"Value of MRI in diagnostics and evaluation of myositis","volume":"28","author":"Pipitone","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2024.02.005_bib36","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.ensci.2022.100442","article-title":"Checkpoint inhibitor induced myositis - The value of MRI STIR","volume":"30","author":"Erritz\u00f8e-Jervild","year":"2023","journal-title":"eNeurologicalSci"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/BOR.0b013e3283118711","article-title":"Imaging tools for the clinical assessment of idiopathic inflammatory myositis","volume":"20","author":"Walker","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.005_bib38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib39","doi-asserted-by":"crossref","first-page":"101765","DOI":"10.1016\/j.berh.2022.101765","article-title":"Muscle imaging in myositis: MRI, US, and PET","volume":"36","author":"Albayda","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2024.02.005_bib40","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors - a systematic review. Systematic Review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.005_bib41","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: a pharmacovigilance study. Observational, retropective, pharmacovigilance","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.005_bib42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated Polymyalgia Rheumatica\/Giant Cell Arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib43","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Basic Science","volume":"114","author":"Zhang","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.005_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCRESAHA.122.322330","article-title":"CTLA-4 Pathway is instrumental in Giant Cell Arteritis. Primary Study","volume":"133","author":"Regnier","year":"2023","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib45","first-page":"266","article-title":"Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review","volume":"8","author":"Lee","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.005_bib46","doi-asserted-by":"crossref","first-page":"e233496","DOI":"10.1136\/bcr-2019-233496","article-title":"Immune checkpoint inhibitor induced large vessel vasculitis. Case Report","volume":"13","author":"Henderson","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.rdc.2024.02.005_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7295305","article-title":"A\u00a0Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim","author":"Mort","year":"2022","journal-title":"Case Reports in Oncological Medicine"},{"key":"10.1016\/j.rdc.2024.02.005_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221852","article-title":"Aftermath of induced inflammation: acute periaortitis due to nivolumab","author":"Roy","year":"2017","journal-title":"Case Report. BMJ Case Reports"},{"key":"10.1016\/j.rdc.2024.02.005_bib49","series-title":"Rheumatology case report: immune-related aortitis associated with Ipilimumab","author":"Ban","year":"2017"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","author":"Padda","year":"2018","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.rdc.2024.02.005_bib51","first-page":"1","article-title":"Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'","author":"Gupta","year":"2020","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.005_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/kex173","article-title":"The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Review","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"issue":"20","key":"10.1016\/j.rdc.2024.02.005_bib53","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1200\/JCO.2012.47.5095","article-title":"Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab. case report","volume":"31","author":"Minor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.005_bib54","first-page":"606","article-title":"Nivolumab-induced systemic vasculitis","volume":"4","author":"Kang","year":"2018","journal-title":"Journal of American Academy of Dermatology Case Reports"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:55:49Z","timestamp":1713988549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000127"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging in Rheumatic Immune-related Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}